Mahmud, N’s team published research in Alimentary Pharmacology and Therapeutics in 2002-02-28 | 6054-98-4

Alimentary Pharmacology and Therapeutics published new progress about C-reactive protein Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 6054-98-4 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H8N2Na2O6, SDS of cas: 6054-98-4.

Mahmud, N.; O’Toole, D.; O’Hare, N.; Freyne, P. J.; Weir, D. G.; Kelleher, D. published the artcile< Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis>, SDS of cas: 6054-98-4, the main research area is mesalazine olsalazine aminosalicylate ulcerative colitis nephrotoxicity microalbuminuria prognosis.

A number of cases of nephrotoxicity have been reported in patients with inflammatory bowel disease taking oral 5-aminosalicylic acid (5-ASA). The aim of this study was to evaluate the effects of 9 mo of therapy with mesalazine or olsalazine on renal function in patients with ulcerative colitis in remission. Forty patients with ulcerative colitis in complete remission for 6 mo were randomized to either olsalazine (n = 20) or mesalazine (n = 20 for nine months). Thirty-six of the 40 patients were on prior salicylate therapy. Disease activity was the measure of clin. efficacy and was assessed by the Harvey-Bradshaw Index (HBI). Laboratory efficacy measurements included glomerular filtration rate (GFR), microalbuminuria, urinary glutathione S-transferase (GST) and serum C-reactive protein (CRP). Safety anal. consisted of documentation of adverse events and laboratory values. There was no significant reduction in the GFR overall on therapy. The levels of GFR adjusted for baseline were similar in the two treatment groups after 3, 6 and 9 mo. A significantly higher percentage of mesalazine-treated patients experienced drug related adverse events, all of a minor nature. The incidence of adverse events causing early withdrawal was similar in the two treatment groups. Treatment with mesalazine or olsalazine for 9 mo had no significant impact on GFR.

Alimentary Pharmacology and Therapeutics published new progress about C-reactive protein Role: BSU (Biological Study, Unclassified), BIOL (Biological Study). 6054-98-4 belongs to class alcohols-buliding-blocks, and the molecular formula is C14H8N2Na2O6, SDS of cas: 6054-98-4.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts